Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE4.3900
- TODAY'S CHANGE (%)-0.2700 (-5.7940%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close4.6700 / 4.6600
- Day Range
- 52 Week Range
- Volume613,025
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 1029 | 4.67 |
| 09:34 ET | 200 | 4.64 |
| 09:36 ET | 200 | 4.66 |
| 09:38 ET | 110 | 4.655 |
| 09:39 ET | 100 | 4.65 |
| 09:43 ET | 605 | 4.6475 |
| 09:45 ET | 100 | 4.645 |
| 09:50 ET | 500 | 4.64 |
| 09:52 ET | 431 | 4.64 |
| 09:54 ET | 100 | 4.63 |
| 09:56 ET | 100 | 4.625 |
| 09:57 ET | 500 | 4.63 |
| 09:59 ET | 1398 | 4.63 |
| 10:01 ET | 600 | 4.63 |
| 10:03 ET | 627 | 4.62 |
| 10:06 ET | 400 | 4.64 |
| 10:10 ET | 300 | 4.63 |
| 10:14 ET | 8047 | 4.6 |
| 10:15 ET | 300 | 4.6 |
| 10:19 ET | 10295 | 4.57 |
| 10:21 ET | 1497 | 4.566 |
| 10:24 ET | 2717 | 4.5598 |
| 10:26 ET | 1100 | 4.555 |
| 10:28 ET | 1086 | 4.5617 |
| 10:30 ET | 5715 | 4.565 |
| 10:32 ET | 1690 | 4.565 |
| 10:33 ET | 2717 | 4.605 |
| 10:37 ET | 800 | 4.59 |
| 10:39 ET | 700 | 4.595 |
| 10:42 ET | 200 | 4.58 |
| 10:44 ET | 125 | 4.585 |
| 10:46 ET | 4100 | 4.59 |
| 10:48 ET | 200 | 4.59 |
| 10:50 ET | 1400 | 4.58 |
| 10:53 ET | 553 | 4.59 |
| 10:55 ET | 200 | 4.58 |
| 10:57 ET | 100 | 4.59 |
| 11:00 ET | 1186 | 4.585 |
| 11:02 ET | 999 | 4.57 |
| 11:04 ET | 3654 | 4.565 |
| 11:06 ET | 125 | 4.5714 |
| 11:08 ET | 1100 | 4.575 |
| 11:09 ET | 700 | 4.58 |
| 11:11 ET | 325 | 4.5799 |
| 11:13 ET | 700 | 4.59 |
| 11:15 ET | 1006 | 4.6092 |
| 11:18 ET | 200 | 4.605 |
| 11:22 ET | 100 | 4.6099 |
| 11:24 ET | 100 | 4.61 |
| 11:29 ET | 3700 | 4.605 |
| 11:31 ET | 400 | 4.605 |
| 11:33 ET | 1000 | 4.615 |
| 11:40 ET | 700 | 4.615 |
| 11:44 ET | 324 | 4.6199 |
| 11:45 ET | 1216 | 4.6007 |
| 11:47 ET | 1500 | 4.585 |
| 11:49 ET | 200 | 4.59 |
| 11:51 ET | 800 | 4.595 |
| 11:56 ET | 159 | 4.59 |
| 11:58 ET | 200 | 4.59 |
| 12:02 ET | 3361 | 4.5799 |
| 12:03 ET | 952 | 4.585 |
| 12:05 ET | 500 | 4.5817 |
| 12:16 ET | 250 | 4.585 |
| 12:18 ET | 1900 | 4.58 |
| 12:20 ET | 944 | 4.585 |
| 12:21 ET | 200 | 4.589 |
| 12:25 ET | 400 | 4.58 |
| 12:30 ET | 1000 | 4.57 |
| 12:36 ET | 500 | 4.58 |
| 12:38 ET | 700 | 4.58 |
| 12:43 ET | 2309 | 4.58 |
| 12:45 ET | 2200 | 4.5893 |
| 12:48 ET | 700 | 4.585 |
| 12:50 ET | 300 | 4.5891 |
| 12:52 ET | 968 | 4.6 |
| 12:54 ET | 1409 | 4.605 |
| 12:57 ET | 200 | 4.6093 |
| 12:59 ET | 3150 | 4.5905 |
| 01:01 ET | 600 | 4.59 |
| 01:03 ET | 3561 | 4.58 |
| 01:08 ET | 2800 | 4.595 |
| 01:12 ET | 16794 | 4.57 |
| 01:14 ET | 400 | 4.575 |
| 01:17 ET | 1400 | 4.56 |
| 01:19 ET | 300 | 4.5543 |
| 01:21 ET | 100 | 4.55 |
| 01:24 ET | 300 | 4.555 |
| 01:26 ET | 2320 | 4.555 |
| 01:30 ET | 6842 | 4.545 |
| 01:32 ET | 7281 | 4.5641 |
| 01:33 ET | 500 | 4.564 |
| 01:35 ET | 375 | 4.565 |
| 01:37 ET | 200 | 4.56 |
| 01:39 ET | 3055 | 4.54 |
| 01:42 ET | 100 | 4.54 |
| 01:44 ET | 1290 | 4.54 |
| 01:46 ET | 600 | 4.545 |
| 01:48 ET | 1093 | 4.55 |
| 01:50 ET | 100 | 4.555 |
| 01:51 ET | 38027 | 4.5158 |
| 01:53 ET | 10474 | 4.505 |
| 01:55 ET | 1620 | 4.51 |
| 01:57 ET | 2415 | 4.51 |
| 02:00 ET | 29113 | 4.4799 |
| 02:02 ET | 17349 | 4.455 |
| 02:04 ET | 9026 | 4.4588 |
| 02:06 ET | 3130 | 4.465 |
| 02:08 ET | 1724 | 4.465 |
| 02:09 ET | 12961 | 4.436 |
| 02:11 ET | 1675 | 4.44 |
| 02:13 ET | 9232 | 4.44 |
| 02:15 ET | 8114 | 4.435 |
| 02:18 ET | 250 | 4.435 |
| 02:20 ET | 9589 | 4.46 |
| 02:22 ET | 1587 | 4.4604 |
| 02:24 ET | 2550 | 4.47 |
| 02:26 ET | 1511 | 4.48 |
| 02:27 ET | 1290 | 4.4791 |
| 02:29 ET | 4941 | 4.47 |
| 02:31 ET | 300 | 4.465 |
| 02:33 ET | 2925 | 4.465 |
| 02:36 ET | 100 | 4.465 |
| 02:38 ET | 100 | 4.465 |
| 02:40 ET | 1635 | 4.46 |
| 02:42 ET | 100 | 4.465 |
| 02:44 ET | 400 | 4.465 |
| 02:45 ET | 2190 | 4.4568 |
| 02:47 ET | 600 | 4.455 |
| 02:51 ET | 100 | 4.45 |
| 02:54 ET | 51747 | 4.455 |
| 02:56 ET | 7638 | 4.445 |
| 02:58 ET | 1081 | 4.44 |
| 03:00 ET | 885 | 4.4349 |
| 03:02 ET | 1050 | 4.43 |
| 03:03 ET | 23368 | 4.41 |
| 03:05 ET | 2964 | 4.4199 |
| 03:07 ET | 8469 | 4.3999 |
| 03:09 ET | 18986 | 4.39 |
| 03:12 ET | 12213 | 4.39 |
| 03:14 ET | 3178 | 4.385 |
| 03:16 ET | 100 | 4.385 |
| 03:18 ET | 4862 | 4.4089 |
| 03:20 ET | 2932 | 4.406 |
| 03:21 ET | 1207 | 4.415 |
| 03:23 ET | 410 | 4.415 |
| 03:25 ET | 567 | 4.415 |
| 03:27 ET | 210 | 4.415 |
| 03:30 ET | 5540 | 4.41 |
| 03:32 ET | 400 | 4.4 |
| 03:34 ET | 400 | 4.405 |
| 03:36 ET | 6016 | 4.405 |
| 03:38 ET | 7510 | 4.3999 |
| 03:39 ET | 1918 | 4.395 |
| 03:41 ET | 4067 | 4.395 |
| 03:43 ET | 5816 | 4.395 |
| 03:45 ET | 3400 | 4.395 |
| 03:48 ET | 6621 | 4.385 |
| 03:50 ET | 400 | 4.38 |
| 03:52 ET | 3960 | 4.385 |
| 03:54 ET | 1600 | 4.38 |
| 03:56 ET | 5633 | 4.385 |
| 03:57 ET | 20398 | 4.365 |
| 03:59 ET | 28172 | 4.39 |
Yesterday
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 675.4M | -13.5x | --- |
Immunome Inc | 883.4M | -2.6x | --- |
Arbutus Biopharma Corp | 813.7M | -9.8x | --- |
4D Molecular Therapeutics Inc | 826.8M | -7.2x | --- |
Erasca Inc | 864.5M | -3.3x | --- |
89Bio Inc | 856.8M | -4.1x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $675.4M |
|---|---|
Revenue (TTM) | $10.4M |
Shares Outstanding | 153.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.99 |
EPS | $-0.33 |
Book Value | $0.46 |
P/E Ratio | -13.5x |
Price/Sales (TTM) | 65.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
